European Journal of Cancer Care最新文献

{"title":"Attitudes toward Cancer Diagnosis Disclosure and Resilience among Suspicious Lung Cancer Patients, Lung Cancer Patients, and Their Families","authors":"Qiongyao Guan, Hailiang Ran, Jiao Yang, Xiumei Yang, Gang Guo, Nan Shen","doi":"10.1155/2023/2273891","DOIUrl":"https://doi.org/10.1155/2023/2273891","url":null,"abstract":"Objective. This study aimed to compare the attitudes and preferences on cancer diagnosis disclosure (CDD) among suspicious lung cancer patients (SLCPs), lung cancer patients (LCPs), and their family members and to explore their associations with resilience. Methods. A cross-sectional study was conducted at Yunnan Cancer Hospital in China, from March to August 2022. A total of 1016 participants including 254 SLCP-family pairs and 254 LCP-family pairs completed self-administered questionnaires to assess their attitudes toward CDD and resilience. Continuous variables were expressed by means and standard deviations, while categorical variables were presented by numbers and percentages. The comparisons between groups were tested by using a t-test or chi-squared test. Associations between resilience and CDD attitudes in the four groups were estimated by multivariate logistic regression models. Results. Compared with LCPs, more SLCPs believed that patients should be informed of their cancer diagnoses (63.8% vs 43.7%, p<0.001), and the distribution of the first one to know the diagnosis was disequilibrium (p<0.05). The significant difference was identified in participants’ attitudes toward patients being told the facts by resilience levels among the different groups. Subsequent multivariate logistic regression analyses showed that resilience was associated with participants’ preference for patients being informed of their cancer diagnoses in the SLCPs group (adjusted OR: 1.87, 95% CI: 1.08–3.25), LCPs group (adjusted OR: 2.21, 95% CI: 1.32–3.74), and family of LCPs group (adjusted OR: 1.79, 95% CI: 1.04–3.12). We further performed a sensitivity analysis using quantiles of resilience. Conclusion. SLCPs and LCPs exhibited different attitudes towards CDD. Resilience plays a positive role in CDD. Our study suggests that healthcare practitioners should consider patients’ diagnosis state when disclosing a cancer diagnosis and tailor their disclosure methods based on the patients’ and families’ preferences and resilience. Our findings provide important implications to guide future research and intervention programs to improve cancer diagnosis disclosure for SLCPs, LCPs, and their families.","PeriodicalId":502476,"journal":{"name":"European Journal of Cancer Care","volume":"8 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139156779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Associated with Adherence to Complete Decongestion Therapy in Women with Breast Cancer-Related Lymphedema","authors":"Fulin Pu, Lijuan Zhang, Yiheng Zhang, Shihao Sun, Na Li, Haifen Liao, Meifen Zhang","doi":"10.1155/2023/6652771","DOIUrl":"https://doi.org/10.1155/2023/6652771","url":null,"abstract":"Background. Adherence to complete decongestion therapy (CDT) is of utmost importance for patients with breast cancer-related lymphedema (BCRL). However, past studies have demonstrated that adherence to CDT in BCRL patients is less than satisfactory. Our study aimed to describe the level of adherence to CDT among BCRL patients and utilize the Health Belief Model to analyse the key factors that influence adherence. Methods. We employed a convenient sampling method to select 158 patients with BCRL who were in the maintenance stage of CDT in a grade A tertiary tumour hospital in Guangzhou. A questionnaire survey was used to investigate patients’ adherence to CDT, as well as their sociodemographic characteristics, medical history characteristics, disease knowledge, and health beliefs. Results. The CDT adherence score of BCRL patients was 96.46 ± 18.46 points, with an average score of 2.61 ± 0.50 points per item. The adherence rate was 65.18 ± 12.47%, indicating a moderate level of adherence. Factors that significantly influenced CDT adherence in BCRL patients included age under 45 years, having 0 or 1 child, experiencing 9 lymphedema symptoms, and having low levels of disease knowledge and health beliefs ( p < 0.05 ). Conclusions. The level of adherence to CDT in BCRL patients is moderate and requires improvement. To enhance adherence to CDT, medical professionals should focus on patients who are younger, have fewer children, exhibit fewer symptoms of lymphedema, possess limited disease knowledge, and have weak health beliefs.","PeriodicalId":502476,"journal":{"name":"European Journal of Cancer Care","volume":"152 6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139208245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic Myeloid Leukaemia: A Qualitative Study of Patient and Practitioner Experiences of Managing Treatment","authors":"A. Hewison, Eve Roman, Alex Smith, D. McCaughan, Rebecca Sheridan, R. Patmore, Karl Atkin, D. Howell","doi":"10.1155/2023/6646271","DOIUrl":"https://doi.org/10.1155/2023/6646271","url":null,"abstract":"Background. Following the dramatic impact of tyrosine kinase inhibitor (TKI) drugs on chronic myeloid leukaemia (CML) survival, research interest has grown into the long-term impact of treatment, identifying difficulties with medication adherence and ongoing side effects. Qualitative studies suggest the disease has a significant physical and psychological impact on patients, and medication management may be complex. However, only one study worldwide has examined healthcare practitioner (HCP) experiences of managing CML treatment and very little UK qualitative research exists exploring the patient experience. Purpose. Our qualitative study aimed to investigate both patient and HCP experiences of managing CML treatment in the UK. Methods. Patients and HCPs were purposively sampled from within the Haematological Malignancy Research Network (HMRN), a UK population-based patient cohort. Qualitative interviews were carried out with seventeen patients and thirteen HCPs, and data were analysed using thematic analysis. Results. Four themes were developed from interview analysis: “Importance of optimal clinical management,” “Multiple adherence strategies,” “Inconsistent management of adherence,” and “Controlling side effects is complex.” HCPs tended to focus on sometimes complex, clinical decision-making. Patients described various strategies to support adherence and manage side effects, some of which HCPs seemed to be less aware of. Several patients did not discuss non-adherence or side effects with their HCP, who tended to avoid direct enquiry regarding adherence and could be uncertain about adherence advice, whilst relying on medical strategies to manage side effects. Conclusions. Despite HCPs focusing on the medical management of CML treatment, patients may opt to use self-management techniques to control adherence and side effects and can be reluctant to discuss related difficulties. Increased clinic time and clear adherence advice guidance may support such discussion, in addition to adjusting the context of follow-up care through the introduction of shared care with GP services.","PeriodicalId":502476,"journal":{"name":"European Journal of Cancer Care","volume":"29 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139236629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Comparative Study of Sleep Parameters in Adult Survivors of Childhood Acute Lymphoblastic Leukemia and Healthy Peers: Insights from Accelerometer Data","authors":"Tomáš Vyhlídal, J. Dygrýn, František Chmelík","doi":"10.1155/2023/8978333","DOIUrl":"https://doi.org/10.1155/2023/8978333","url":null,"abstract":"Background. Sleep problems are among the common late side effects of treatment that can occur in survivors of childhood acute lymphoblastic leukemia. At present, the objective evaluation of sleep in the natural environment using actigraphy rather than self-assessment of research participants or the more demanding polysomnography is increasingly coming to the forefront in population epidemiological studies. The main objective of this cross-sectional study is to objectively characterize selected sleep parameters with respect to gender in adult survivors of childhood acute lymphoblastic leukemia (ALS) in their natural environment and to compare them with a control group (CG) sampled from a healthy population. Another partial aim of the study is to determine the fulfillment of recommendations in the areas of sleep (SL) and sleep efficiency (SE). Methods. 20 ALS and 20 CGs aged 18–30 years participated in the survey. The ALS were diagnosed on average 15.5 years ago. Selected sleep parameters were measured instrumentally by means of an Axivity AX3 accelerometer worn on the wrist for seven days in a natural environment. Results. No significant differences were found between the ALS and CG groups for the selected sleep parameters. The total time in bed for the ALS was 405.5 min/day compared to 428.2 min/day for the CG ( p = 0.37 ), sleep for the ALS was 372.7 min/day compared to 382.9 min/day for the CG ( p = 0.34 ), and SE for the ALS was 88.0% compared to 88.5% for the CG ( p = 0.99 ). No significant gender differences were found. The sleep recommendation of >420 min/day was met by 15% for the ALS and 19% for the CG; SE > 85% was achieved by 80% for the ALS and 80% for the CG. Conclusion. The results of our study suggest that ALS may achieve the same values as the healthy population in selected sleep parameters.","PeriodicalId":502476,"journal":{"name":"European Journal of Cancer Care","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139248782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}